News and press announcements

Interaction between pharmaceutical companies and medical professionals in COVID situation

May 12, 2020, Sofia

The Association of the Research-based Pharmaceutical Manufacturers (ARPharM) and its member companies are committed to the global fight against the COVID-19 pandemic due to coronavirus. Our thoughts are with the people affected by the infection and their loved ones, as well as with the doctors and pharmacists who are at the forefront in the fight to overcome the pandemic.

The Research-based pharmaceutical industry is focused on three key areas: • the development of new vaccines, diagnostics and drug therapies to combat COVID-19 - around 7 vaccine applicants and over 30 antiviral drugs at various stages of development or use are currently being investigated by innovative pharmaceutical companies in over 25 clinical trials to determine whether they are effective in preventing or treating patients with COVID-19 - http://arpharm.org/index.php?id=1245;

read more
Coronavirus – your questions answered

Q. What is a coronavirus? Coronaviruses are a large family of viruses which may cause illness in animals or humans. In humans, several coronaviruses are known to cause respiratory infections ranging from the common cold to more severe diseases such as Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS). The most recently discovered coronavirus causes coronavirus disease COVID-19.

COVID-19 is the infectious disease caused by the most recently discovered coronavirus. This new virus and disease were unknown before the outbreak began in Wuhan, China, in December 2019.

read more
What’s next?

12/05/2019 Diseases will not give up or disappear. Luckily, neither will science nor researchers. Just as they didn’t in the 1980s when the needle and the syringe were the only known way of injecting insulin, or in the 1990s when HIV meant a death penalty, or in the 2000s when destroying the cancer cells also affected the healthy cells.

What would it mean to slow down the beginning of Alzheimer’s disease? Could antibodies slow down our resistance to antibiotics and help overcome bacterial infections? What cell therapies would it take to avoid having aggressive chemotherapy ever again? And is there potential for gene therapy to reduce the toll of lifelong treatment?

read more

Campaigns

Awareness Week 19-23 November 2018

Make your use of medicines safer: report suspected adverse reactions in children and during pregnancy.

For the second year, the Bulgarian Drugs Agency (BDA) launched an online campaign to promote the importance of reporting suspected adverse drug reactions.

The campaign, to be held from 19-23 November 2018, is part of an "awareness week" involving 32 EU, Latin American, Australian, New Zealand and Middle East medicines regulators. Regulatory bodies will jointly focus on enhancing the reporting of suspected adverse reactions in infants and children as well as during pregnancy and lactation.

read more

#WeWontRest

We were born to end patients’ suffering.

To extend life and improve its quality.

That’s why in the 70s, when infectious diseases passed from person to person, we didn’t rest.

In the 80s, when a needle and syringe was the only option for insulin injection, we didn’t rest.

In the 90s, when contracting HIV was a death sentence, we didn’t rest.

In the 2000s, when killing cancer cells damaged healthy cells too, we didn’t rest.

And right now, after decades of tireless medical innovation, we still won’t rest.

read more

Members of the Association